Danaher: Q2 Earnings Insights

Shares of Danaher DHR moved higher by 2.1% in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share were up 21.01% year over year to $1.44, which beat the estimate of $1.08.

Revenue of $5,297,000,000 higher by 2.71% year over year, which beat the estimate of $4,940,000,000.

Looking Ahead

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

How To Listen To The Conference Call

Date: Jul 23, 2020

Time: 08:00 AM

ET Webcast URL: https://www.webcaster4.com/Webcast/Page/758/35318

Price Action

Company's 52-week high was at $197.18

Company's 52-week low was at $119.60

Price action over last quarter: Up 19.65%

Company Description

In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in four segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which adds to its life sciences segment.